Roth Capital reiterated a Buy rating on Natus Medical (NASDAQ: BABY), and raised the price target to $53.00 (from $51.00), following the company's 3Q15 earnings results. BABY continues to outperform expectations, with 3Q non-GAAP operating margin of 19.9%.

Analyst Chris Lewis commented, "We remain bullish on BABY after another beat-and-raise quarter, highlighted by sustained revenue growth and continued operating margin expansion. BABY’s emerging service offering (Peloton, GND, NicView, HCC) along with new product / pipeline, leave us confident BABY can sustain core (excluding Venezuela) revenue growth at least in the mid-single digits."

For an analyst ratings summary and ratings history on Natus Medical click here. For more ratings news on Natus Medical click here.

Shares of Natus Medical closed at $45.00 yesterday.